Search Result

Results for "

ATP-binding domains

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Bacterial (2) BMX Kinase (1) Btk (1) DNA/RNA Synthesis (2) EGFR (2) Ephrin Receptor (1) FGFR (1) FLT3 (1) HSP (1) IAP (1) IRE1 (2) JAK (2) LIM Kinase (LIMK) (1) NEDD8-activating Enzyme (1) NOD-like Receptor (NLR) (3) PARP (1) PI3K (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) Reverse Transcriptase (1) Ribosomal S6 Kinase (RSK) (1) RIP kinase (1) Ser/Thr Kinase (1) STAT (1) Trk Receptor (2) VEGFR (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (8) Neurological Disease (1)

By Targets:

Apoptosis (4)

Bacterial (2)

BMX Kinase (1)

Btk (1)

DNA/RNA Synthesis (2)

EGFR (2)

Ephrin Receptor (1)

FGFR (1)

FLT3 (1)

HSP (1)

IAP (1)

IRE1 (2)

JAK (2)

LIM Kinase (LIMK) (1)

NEDD8-activating Enzyme (1)

NOD-like Receptor (NLR) (3)

PARP (1)

PI3K (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

Reverse Transcriptase (1)

Ribosomal S6 Kinase (RSK) (1)

RIP kinase (1)

Ser/Thr Kinase (1)

STAT (1)

Trk Receptor (2)

VEGFR (1)

By Research Areas:

Cancer (10)

Cardiovascular Disease (1)

Infection (3)

Inflammation/Immunology (8)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: ATP-binding cassette (ABC) transporters P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50867

Lestaurtinib 4 Publications Verification CEP-701; KT-5555	JAK FLT3 Trk Receptor Apoptosis STAT	Cancer
Lestaurtinib (CEP-701) is an orally active and selective RPTKs (receptor protein tyrosine kinase) inhibitor, competitively inhibits ATP binding to the TrkA/B/C domain. Lestaurtinib inhibits RPTKs phosphorylation, with IC₅₀s of 2, 25 and 0.9 nM for FLT3, TrkA and JAK2, respectively. Lestaurtinib induces apoptosis and cycle arrest, also can inhibit growth of tumor .

HY-103666

CY-09 Maximum Cited Publications 50 Publications Verification	NOD-like Receptor (NLR)	Inflammation/Immunology
CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation .

HY-17537

APY29 10+ Cited Publications	IRE1	Cancer
APY29, an ATP-competitive inhibitor, is an allosteric modulator of IRE1α which inhibits IRE1α autophosphorylation by binding to the ATP-binding pocket with IC₅₀ of 280 nM. APY29 acts as a ligand that allosterically activates IRE1α adjacent RNase domain .

HY-80002

BMX-IN-1 5+ Cited Publications BMX kinase inhibitor	Btk BMX Kinase	Cancer
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys ⁴⁹⁶ in the BMX ATP binding domain with an IC₅₀ of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC₅₀ value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.

HY-122616

PF-06273340	Trk Receptor	Neurological Disease
PF-06273340 is a peripherally restricted pan-Trk inhibitor with IC₅₀ values of 6, 4, 3 nM for TrkA, TrkB, and TrkC receptors. PF-06273340 binds in a DFG-out conformation, targeting less conserved kinase ligand binding domain regions outside the ATP binding pocket. PF-06273340 exhibits anti-hyperalgesic and analgesic effects. PF-06273340 can be used for the research of pain .

HY-120097

R-10015	LIM Kinase (LIMK) Reverse Transcriptase	Infection
R-10015, a broad-spectrum antiviral compound for HIV infection, acts as a potent and selective inhibitor of *LIM domain* kinase (LIMK)** and binds to the ATP-binding pocket, with an IC₅₀ of 38 nM for human LIMK1 .

HY-114977

Avenanthramide A	DNA/RNA Synthesis Apoptosis Reactive Oxygen Species (ROS)	Inflammation/Immunology Cancer
Avenanthramide A is an orally active phytoalexin that targets the RNA helicase DDX3 with a K_D of 8.8 μM. Avenanthramide A induces mitochondrial swelling and increased ROS production, and triggers apoptosis in CRC cells. Avenanthramide A inhibits smooth muscle cell proliferation and enhances nitric oxide production. Avenanthramide A can be used in research on colorectal cancer and atherosclerosis .

HY-145425

PAIR2	IRE1 Apoptosis FGFR	Inflammation/Immunology
PAIR2 is a highly selective inhibitor targeting the kinase domain of human IRE1α, with a K_i value of 8.8 nM against human IRE1α. PAIR2 fully occupies the ATP-binding site of the IRE1α kinase domain, partially antagonizes the ribonuclease activity of IRE1α, specifically inhibits regulated IRE1α-dependent decay (RIDD) and its mediated substrate cleavage, while preserving the splicing function of Xbp1 mRNA. PAIR2 also promotes the differentiation of B cells into plasma cells, blocks IRE1α-induced cell apoptosis, and restores the expression of Fgfr2 mRNA in AT2 cells. PAIR2 effectively reaches a steady-state concentration in the lung tissues of Mus musculus, and serves as an important tool for investigating the function of the IRE1α signaling pathway in diseases such as pulmonary fibrosis .

HY-177936

NAE-IN-3	NEDD8-activating Enzyme	Cancer
NAE-IN-3 (compound 1) is a potent, selective and non-covalent competitive NEDD8-activating enzyme (NAE) inhibitor (IC₅₀ = 0.8 μM). NAE-IN-3 inhibits NAE by blocking the ATP-binding domain. NAE-IN-3 exhibits selectivity over analogous E1 enzymes UAE and SAE. NAE-IN-3 can be used for cancer research .

HY-P11053

A17 peptide	HSP	Cancer
A17 peptide is a Hsp70-targeting peptide. A17 peptide binds to the ATP-binding domains of Hsp70. A17 peptide specifically inhibits the chaperone activity, thereby increasing the cells' sensitivity to apoptosis induced by chemotherapeutic agents, such as Cisplatin (HY-17394). A17 peptide can be used for anticancer chemotherapy research, such multiple myeloma .

HY-122735

Inh2-B1	Ser/Thr Kinase Bacterial	Infection
Inh2-B1 is a Ser/Thr protein kinase (STK1) inhibitor. Inh2-B1 specifically inhibits STK1 activity by directly binding to its ATP-binding catalytic domain. Inh2-B1 down-regulates cell wall hydrolase genes and disrupts the biofilm formation of Methicillin-resistant Staphylococcus aureus (MRSA) clearly .

HY-W286614

RSK2-IN-4	Ribosomal S6 Kinase (RSK)	Inflammation/Immunology Cancer
RSK2-IN-4 (Compound 10) is a RSK2 inhibitor, with an inhibition rate of 13.73% on RSK2 activity at 10 μM. RSK2-IN-4 binds to the ATP-binding site of RSK2 in the NTKD (N-terminal kinase domain), with the electron-donating group at the 4-position of the phenyl ring being the key determinant for its inhibitory activity .

HY-155975

PI3Kδ-IN-14	PI3K	Inflammation/Immunology
PI3Kδ-IN-14 (Compound (S)-29) is a selective PI3Kδ inhibitor (IC₅₀: 0.8 nM, K_d: 84.8 nM). PI3Kδ-IN-14 binds to the ATP-binding site of the kinase domain of PI3Kδ. PI3Kδ-IN-14 has anti-inflammatory activity by inhibiting the PI3K/AKT pathway. PI3Kδ-IN-14 ameliorates acute lung injury (ALI) .

HY-182936

Antibacterial agent 338	Bacterial DNA/RNA Synthesis	Infection
Antibacterial agent 338 (Compound 65) is an antibacterial agent and GyrB inhibitor, with an IC₅₀ of 12.60 nM against GyrB from E. coli. Antibacterial agent 338 binds to the ATP-binding domain of E. coli GyrB, thereby inhibiting the ATPase activity of GyrB. Antibacterial agent 338 exhibits broad-spectrum antibacterial activity against multidrug-resistant Gram-negative bacteria. Antibacterial agent 338 reduces bacterial load in a neutropenic mouse thigh infection model. Antibacterial agent 338 can be used for the research of Acinetobacter baumannii infection .

HY-123925

CSLP43	RIP kinase IAP NOD-like Receptor (NLR)	Inflammation/Immunology
CSLP43 is a selective RIPK2 and XIAP inhibitor with an IC₅₀ of 19.9 nM against human RIPK2. CSLP43 binds to the ATP-binding pocket of RIPK2 and disrupts the interaction between RIPK2 and the BIR2 domain of XIAP or cIAP1. CSLP43 inhibits RIPK2 ubiquitination, NOD1-dependent inflammatory signaling pathways, NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation associated with NOD agonists. CSLP43 is selective for the NOD1/NOD2 signaling pathway and does not inhibit the kinase activity of RIPK1 or RIPK3. CSLP43 is applicable to research related to Crohn's disease, Blau syndrome, early-onset sarcoidosis and early-onset inflammatory bowel disease .

HY-103666R

CY-09 (Standard)	Reference Standards NOD-like Receptor (NLR)	Inflammation/Immunology
CY-09 (Standard) is the analytical standard of CY-09 (HY-103666). This product is intended for research and analytical applications. CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation .

HY-112783

TYK2 ligand 4	JAK	Inflammation/Immunology
TYK2 ligand 4 (Compound 2) is a TYK2 ligand. TYK2 ligand 4 binds to both the kinase domain and pseudokinase domain, and induces an inactive conformation of the kinase domain, thereby preventing ATP binding. TYK2 ligand 4 serves as a tool compound for the development of Deucravacitinib (HY-117287) .

HY-183373

EGFR/PARP-1-IN-1	EGFR PARP	Cancer
EGFR/PARP-1-IN-1 is a dual EGFR and PARP-1 inhibitor with IC₅₀ values of 64 nM and 12 nM, respectively. EGFR/PARP-1-IN-1 binds to the ATP-binding pocket of EGFR and interacts with the catalytic domain of PARP-1, inhibiting kinase and enzymatic activity via hydrogen bond formation with key residues in both targets. EGFR/PARP-1-IN-1 induces apoptosis through the endogenous mitochondrial pathway, arrests the cell cycle at the G2 phase, and inhibits cell proliferation. EGFR/PARP-1-IN-1 can be used for research on triple-negative breast cancer .

HY-10654

EphB4-IN-2	Ephrin Receptor	Cancer
EphB4-IN-2 (compound 66) is a tyrosine kinase inhibitor with an IC₅₀ value of 1.6 nM against human EphB4, and exhibits selectivity toward kinases bearing threonine gatekeeper residues. EphB4-IN-2 also has high ligand efficiency .

HY-182073

EGFR-IN-207	EGFR Apoptosis	Cancer
EGFR-IN-207 (Compound 5h) is an epidermal growth factor receptor (EGFR) kinase inhibitor with an IC₅₀ of 0.21 μM. EGFR-IN-207 induces cell cycle arrest at the Sub-G1 phase and promotes Apoptosis. EGFR-IN-207 exhibits anticancer activity against lung cancer. EGFR-IN-207 shows extremely low toxicity in non-cancerous cell lines. EGFR-IN-207 can be used in lung cancer-related research .

HY-182306

VEGFR-2 ligand-2	VEGFR	Cardiovascular Disease
VEGFR-2 ligand-1, Sorafenib (HY-10201) derivative, is a vascular endothelial growth factor receptor 2 (VEGFR2) ligand. VEGFR-2 ligand-1 binds to the ATP-binding pocket of VEGFR2, forms hydrophobic contacts and hydrogen bonds with key binding-site residues. VEGFR-2 ligand-1 can be used for the research angiogenesis-related pathologies .

Cat. No.	Product Name	Target	Research Area

HY-P11053

A17 peptide	HSP	Cancer
A17 peptide is a Hsp70-targeting peptide. A17 peptide binds to the ATP-binding domains of Hsp70. A17 peptide specifically inhibits the chaperone activity, thereby increasing the cells' sensitivity to apoptosis induced by chemotherapeutic agents, such as Cisplatin (HY-17394). A17 peptide can be used for anticancer chemotherapy research, such multiple myeloma .

Avenanthramide A	Structural Classification Avena sativa Linn. Gramineae Phenols Polyphenols Plants Source Classification	DNA/RNA Synthesis Apoptosis Reactive Oxygen Species (ROS)
Avenanthramide A is an orally active phytoalexin that targets the RNA helicase DDX3 with a K_D of 8.8 μM. Avenanthramide A induces mitochondrial swelling and increased ROS production, and triggers apoptosis in CRC cells. Avenanthramide A inhibits smooth muscle cell proliferation and enhances nitric oxide production. Avenanthramide A can be used in research on colorectal cancer and atherosclerosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks